PMC

SP1 overexpression reverses the pro-apoptotic effect of cannabidiol in vivo. A. The tumors of four groups were isolated and compared. B. Tumor growth curve of Sham group, Cannabidiol + Lv-OE-SP1 group, Cannabidiol + Lv-OE-NC group and Cannabidiol group (n=4 per group). Tumor volume was measured every few days. C. Tumor weight was measured at the end of the experiment. D-G. The protein levels of BAX, Bcl2, cleaved caspase-3 and CBX2 in the Sham group, Cannabidiol group, Cannabidiol + Lv-OE-SP1 group, and Cannabidiol + Lv-OE-NC group. The data shown are mean ± SD. **P<0.01 vs. Sham; #P<0.05, ##P<0.01 vs. Cannabidiol + Lv-OE-NC.

CBD = cannabidiol, EEG = electroencephalogram.

a Target-mediated drug–drug interactions of cannabidiol with cannabinoid and 5-hydroxytryptamine 1A receptors . b Target-mediated drug–drug interactions of cannabidiol with 5-hydroxytryptamine 2A receptors . c Target-mediated drug–drug interactions of cannabidiol with 5-hydroxytryptamine 3A receptors . d Target-mediated drug–drug interactions of cannabidiol with prostaglandin G/H synthase 1 and 2 inhibitors . e Target-mediated drug–drug interactions of cannabidiol with Cytochrome P450 1B1 and 3A5 inhibitor . f Target-mediated drug–drug interactions of cannabidiol with Cytochrome P450 2D6 and 3A7 inhibitor . g Target-mediated drug–drug interactions of cannabidiol with Cytochrome P450 1A2 inhibitor . The red dotted lines indicate CBD’s mechanism/actions as listed in red boxes. The blue double-headed arrows indicate the possible targets and interactions of CBD with other targets/mechanisms as listed in blue boxes. Green single-headed arrows indicate the drugs that act on these targets, as listed in green boxes. Such drugs may have additive/synergistic or antagonistic effects if given concomitantly with CBD.

Time-kill curves for polymyxin B (PMB) and cannabidiol (CBD) monotherapies and in combinations against polymyxin B-susceptible A. baumannii strain ATCC 19606 (polymyxin B MIC = 1 mg/L, cannabidiol MIC > 64 mg/L) and polymyxin B-resistant A. baumannii strain FADDI-AB144 (polymyxin B MIC = 8 mg/L, cannabidiol MIC > 64 mg/L); against polymyxin B-susceptible K. pneumoniae FADDI-KP002 (polymyxin B MIC = 0.5 mg/L, cannabidiol MIC > 64 mg/L) and polymyxin B-resistant K. pneumoniae FADDI-KP012 (polymyxin B MIC = 32 mg/L, cannabidiol MIC > 64 mg/L); against polymyxin B-resistant P. aeruginosa strains FADDI-PA070 (polymyxin B MIC = 128 mg/L, cannabidiol MIC > 64 mg/L) and FADDI-PA006 (polymyxin B MIC = 8 mg/L, cannabidiol MIC > 64 mg/L). Data are mean values of three independent cultures, and vertical bars represent the standard deviations. Error bars are too small to appear in the graphs.